Personalized 3D Tumoroids from Your Tumor to Test Treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective observational study that collects blood samples and existing tumor tissue to develop and validate 3D, vascularized tumoroids derived from a patient’s own tumor. The project aims to create a panel of personalized tumoroids with perfused vasculature and patient-derived immune components for potential use in guiding urological cancer treatment. Data and samples are used under a biobank protocol, with emphasis on translational aims to bridge laboratory models and clinical care. Participants provide approximately 10 ml of blood per contributing patient to support the tumoroid development process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Inclusion criteria:

* Criteria common to all patients:

  * Male or female subject (≥18 years old);
  * Diagnosed with kidney cancer, prostate cancer, or bladder cancer;
  * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677);
  * affiliated with a social security health insurance scheme or beneficiary of such a scheme;
  * agreeing to participate in the 3DBlood study.
* Specific criteria for patients with renal cell carcinoma (RCC):

  * Extended nephrectomy (EN) (larger tumor, closer to the sinus; therefore at greater risk of metastasis): with a cavo, cavectomy (neoplastic thrombus in the vena cava), or renal vein bud, or lymph node dissection, or with adrenalectomy (often for tumors, therefore possible metastases).

Or

\- Partial nephrectomy (PN): with tumors at stage T2 or T3a)

Exclusion Criteria:

* Patient refusal to participate in the study;
* Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.);
* Patient under legal protection, guardianship, or conservatorship;
* Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).

Where it's running

• Service de Chirurgie Urologique _ Hôpitaux Universitaires de Strasbourg
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Hervé LANG, PUPH
• Email: Herve.Lang@chru-strasbourg.fr
• Phone: 33369550974

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• AI assistant to help diagnose and treat urological diseases

  A large language model-based AI tool called UroAgent will be developed and tested to help doctors diagnose and plan treatment for urinary stones, prostate cancer, and bladder cancer using past records and new patient data.

  Recruiting at 3 sites Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 2 other locations · NCT07721935

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Timing smartphone messages to boost activity for older cancer survivors with chronic pain

  This study tests whether sending short smartphone messages at certain times can increase physical activity in older cancer survivors with chronic pain.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07227077

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Work status and return to work after treatment for bladder, prostate, and kidney cancers and urinary stones

  This project will test how treatment for bladder, prostate, or kidney cancer and procedures for urinary stones affect whether adult patients can return to work and their quality of life.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT07088536

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.